ACS (excluding AMI): 1 trials - Canadian (sulfinpyrazone alone)
| sulfinpyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | no data | | cardiovascular events | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | ischemic stroke | no data | | Vascular death | no data | | Non vascular death | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | no data | | Non fatal stroke | no data | | fatal bleeding | no data | | Bleeding | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Canadian (sulfinpyrazone alone)
| sulfinpyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | no data | | cardiovascular events | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | ischemic stroke | no data | | Vascular death | no data | | Non vascular death | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | no data | | Non fatal stroke | no data | | fatal bleeding | no data | | Bleeding | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
STEMI patients: 3 trials - Dutch sulphinpyrazone - Wilcox - Louvain sulphinpyrazone
| sulfinpyrazone vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.50 [0.09 2.86] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Cardiovascular death | 0.50 [0.09 2.86] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Non fatal MI | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | non cardiovascular death | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Non fatal stroke | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Major bleeding | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sulfinpyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 4.89 [0.81 29.35] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Cardiovascular death | 4.89 [0.81 29.35] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Non fatal MI | no data | | non cardiovascular death | 0.97 [0.06 15.95] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 3 trials - Dutch sulphinpyrazone - Wilcox - Louvain sulphinpyrazone
| sulfinpyrazone vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.50 [0.09 2.86] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Cardiovascular death | 0.50 [0.09 2.86] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Non fatal MI | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | non cardiovascular death | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Non fatal stroke | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, | | Major bleeding | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Dutch sulphinpyrazone, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| sulfinpyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 4.89 [0.81 29.35] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Cardiovascular death | 4.89 [0.81 29.35] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Non fatal MI | no data | | non cardiovascular death | 0.97 [0.06 15.95] | p=1.00 | 0 | 127 | 2 | Wilcox,Louvain sulphinpyrazone, | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Baur
| sulfinpyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 2.88 [0.76 10.91] | p=1.00 | 0 | 255 | 1 | Baur, | | Cardiovascular death | 2.88 [0.12 71.49] | p=1.00 | 0 | 255 | 1 | Baur, | | Non vascular death | 0.96 [0.02 48.84] | p=1.00 | 0 | 255 | 1 | Baur, | | Non fatal MI | 2.56 [0.66 9.90] | p=1.00 | 0 | 255 | 1 | Baur, | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Diabetic patients : 1 trials - Dutch
| sulfinyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| unstable angina | no data | | stable angina | no data | | Peripheral vascular events | no data | | cardiovascular events | 2.07 [0.35 12.23] | p=1.00 | 0 | 61 | 1 | Dutch, | | Cardiovascular death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | Fatal MI | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | Fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Dutch
| sulfinyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| unstable angina | no data | | stable angina | no data | | Peripheral vascular events | no data | | cardiovascular events | 2.07 [0.35 12.23] | p=1.00 | 0 | 61 | 1 | Dutch, | | Cardiovascular death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | Fatal MI | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | Fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients without cardiovascular disease: 1 trials - Dutch
| sulfinyrazone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| unstable angina | no data | | stable angina | no data | | Peripheral vascular events | no data | | cardiovascular events | 2.07 [0.35 12.23] | p=1.00 | 0 | 61 | 1 | Dutch, | | Cardiovascular death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death | no data | | Fatal MI | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 5.17 [0.24 112.40] | p=1.00 | 0 | 61 | 1 | Dutch, | | Fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
